The present invention provides a Sarcopoterium spinosum extract (SSE) for use in preventing or treating inflammation in a subject, and methods for treating inflammation in a subject by administering Sarcopoterium spinosum extract (SSE).

The present invention provides a Sarcopoterium spinosum extract (SSE) for use in preventing or treating inflammation in a subject, and methods for treating inflammation in a subject by administering Sarcopoterium spinosum extract (SSE).

This invention relates to new uses of Bifidobacteria (particularly, although not exclusively, probiotic Bifidobacteria), and to food products, feed products, dietary supplements and pharmaceutical formulations containing them. The bacteria are suitable for the treatment of diabetes (particularly Type 2 diabetes), obesity and related conditions, metabolic syndrome, insulin resistance, and impaired glucose metabolism and consequences thereof, lowering tissue inflammation, treating hepatitis, myositis and cardiovascular conditions.

This invention relates to new uses of Bifidobacteria (particularly, although not exclusively, probiotic Bifidobacteria), and to food products, feed products, dietary supplements and pharmaceutical formulations containing them. The bacteria are suitable for the treatment of diabetes (particularly Type 2 diabetes), obesity and related conditions, metabolic syndrome, insulin resistance, and impaired glucose metabolism and consequences thereof, lowering tissue inflammation, treating hepatitis, myositis and cardiovascular conditions.

Disclosed are nutritional compositions including human milk oligosaccharides that can be administered to preterm infants, term infants, toddlers, and children for improving airway defense mechanisms.

Disclosed are nutritional compositions including human milk oligosaccharides that can be administered to preterm infants, term infants, toddlers, and children for improving airway defense mechanisms.

A method for treating an immune disease caused by a Th1/Th2 imbalance in favor of a Th2 shift in a subject including administering a composition comprising Lactobacillus plantarum CJLP133 strain KCTC 11403BP to the subject in need thereof.

A method for treating an immune disease caused by a Th1/Th2 imbalance in favor of a Th2 shift in a subject including administering a composition comprising Lactobacillus plantarum CJLP133 strain KCTC 11403BP to the subject in need thereof.

The present invention provides compositions and methods for the treatment and prevention of COVID-19. The disclosed compositions comprise a combination of the natural compounds zinc, quercetin, vitamin E, and epigallocatechin gallate (EGCG), and are formulated for use in treating COVID-19, reducing the severity of disease, and enhancing the immune response to vaccination for COVID-19.

The present invention provides compositions and methods for the treatment and prevention of COVID-19. The disclosed compositions comprise a combination of the natural compounds zinc, quercetin, vitamin E, and epigallocatechin gallate (EGCG), and are formulated for use in treating COVID-19, reducing the severity of disease, and enhancing the immune response to vaccination for COVID-19.